In ACMG published guidance for reporting secondary findings in the context of clinical exome and genome sequencing, RAD51C and RAD51D mutations were not listed in SF v3.1 and were no longer being reported as secondary findings, with comments on moderate risk of primarily later-onset breast cancer and low penetrance for ovarian cancer [39]. This evidence concerns the gene RAD51D and ovarian carcinoma.